Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago

31
Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago

TAGS:

description

Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago. Third-Generation EGFR TKIs. EGFR Inhibitors Following Progression on EGFR-Directed Therapy Preliminary Efficacy Comparison. Antiangiogenic Agents in Advanced NSCLC. - PowerPoint PPT Presentation

Transcript of Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago

Page 1: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago

Decision Making in the Era of Individualized Treatment in

Advanced NSCLC:Highlights From Chicago

Page 2: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago

Third-Generation EGFR TKIs

Page 3: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago
Page 4: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago
Page 5: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago

EGFR Inhibitors Following Progression on EGFR-Directed

TherapyPreliminary Efficacy Comparison

Page 6: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago

Antiangiogenic Agents in Advanced NSCLC

Page 7: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago
Page 8: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago
Page 9: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago

First-line Therapy in Advanced NSCLC

Page 10: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago
Page 11: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago
Page 12: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago
Page 13: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago
Page 14: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago

Targeting MET in Advanced NSCLC

Page 15: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago

Global Phase 3 Trial (METLung)* of Onartuzumab

Plus Erlotinib in NSCLC Trial Design

Page 16: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago

METLung TrialOverall Survival Results

Page 17: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago

Crizotinib in Advanced MET-amplified NSCLC

Patient Eligibility: NSCLC MET Amplification Cohort

Page 18: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago
Page 19: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago

Characteristics of Patients With ALK-Positive Disease; Second- Generation ALK

Inhibitors

Page 20: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago
Page 21: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago

ASCEND-1 Trial: Ceritinib in ALK-Positive Advanced NSCLC

Best Percentage Change From Baseline

Page 22: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago

Immune Checkpoint Inhibitor Therapy in Advanced NSCLC

Page 23: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago
Page 24: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago

Abbreviations

Page 25: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago

Abbreviations (cont)

Page 26: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago

References

Page 27: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago

References (cont)

Page 28: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago

References (cont)

Page 29: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago

References (cont)

Page 30: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago

References (cont)

Page 31: Decision Making in the Era of Individualized Treatment in Advanced NSCLC: Highlights From Chicago

References (cont)


Biomarker testing in non- small cell lung cancer (NSCLC) · NSCLC is both histologically and genetically diverse. 3. Prevalence of genetic alterations in NSCLC. 4. 40%. 25%. 10%.

Biomarker testing in non- small cell lung cancer (NSCLC) · NSCLC is both histologically and genetically diverse. 3. Prevalence of genetic alterations in NSCLC. 4. 40%. 25%. 10%.

Lungenkarzinom Nicht Kleinzellig Nsclc A

Lungenkarzinom Nicht Kleinzellig Nsclc A

Concurrent ChemoRT in NSCLC

Concurrent ChemoRT in NSCLC

nonsquamous NSCLC

nonsquamous NSCLC

Connecticut Individualized Education Plan Form ... IEP... · Connecticut Individualized Education Plan Form Instructions and User Guide ... An Individualized Education Plan ...

Connecticut Individualized Education Plan Form ... IEP... · Connecticut Individualized Education Plan Form Instructions and User Guide ... An Individualized Education Plan ...

Update Nsclc

Update Nsclc

NSCLC - InOncology · 2020-06-15 · NSCLC, the most common type of lung cancer, is genomically diverse ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; NSCLC,

NSCLC - InOncology · 2020-06-15 · NSCLC, the most common type of lung cancer, is genomically diverse ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; NSCLC,

CCO Metastatic NSCLC Slides

CCO Metastatic NSCLC Slides

Maintenance therapy for NSCLC

Maintenance therapy for NSCLC

Immune checkpoint inhibitors in NSCLC - OncologyPRO€¦ · Dxnot approved fordurvalumabin any setting Dxnot approved foravellumabin US/EU: any setting NSQ NSCLC EU: NSQ NSCLC Approved

Immune checkpoint inhibitors in NSCLC - OncologyPRO€¦ · Dxnot approved fordurvalumabin any setting Dxnot approved foravellumabin US/EU: any setting NSQ NSCLC EU: NSQ NSCLC Approved

Individualized Tx in NSCLC: How Do We Tackle Advanced Squamous Cell Ca of the Lung Corey J Langer MD, FACP Professor of Medicine Director of Thoracic Oncology.

Individualized Tx in NSCLC: How Do We Tackle Advanced Squamous Cell Ca of the Lung Corey J Langer MD, FACP Professor of Medicine Director of Thoracic Oncology.

Locally Advanced Nsclc

Locally Advanced Nsclc

MARYLAND STATEWIDE INDIVIDUALIZED EDUCATION PROGRAM (IEP ... · INDIVIDUALIZED EDUCATION PROGRAM (IEP) PROCESS GUIDE October 1, 2017 ... Maryland Statewide Individualized Education

MARYLAND STATEWIDE INDIVIDUALIZED EDUCATION PROGRAM (IEP ... · INDIVIDUALIZED EDUCATION PROGRAM (IEP) PROCESS GUIDE October 1, 2017 ... Maryland Statewide Individualized Education

Immune therapy in NSCLC

Immune therapy in NSCLC

ZIRKULIERENDE MICRO-RNA IN NSCLC | NSCLC-TAG ST. GALLEN | 5/1/2014 Zirkulierende micro-RNA in Patienten mit NSCLC PD Dr. med. et rer. nat. M. Joerger Medizinische.

ZIRKULIERENDE MICRO-RNA IN NSCLC | NSCLC-TAG ST. GALLEN | 5/1/2014 Zirkulierende micro-RNA in Patienten mit NSCLC PD Dr. med. et rer. nat. M. Joerger Medizinische.

Treatment of ALK Positive Advanced NSCLC · Treatment of ALK Positive Advanced NSCLC ... • First identified in NSCLC cells in 2007 ... Chemistry of ALK Tyrosine Kinase Inhibitors

Treatment of ALK Positive Advanced NSCLC · Treatment of ALK Positive Advanced NSCLC ... • First identified in NSCLC cells in 2007 ... Chemistry of ALK Tyrosine Kinase Inhibitors

Second line therapy for nsclc

Second line therapy for nsclc

Gevolgen van PATH project voor NSCLC - Zorg … van PATH project voor NSCLC Hoe tillen we Moleculaire Diagnostiek van NSCLC naar hoger plan ? Ed Schuuring KMBP (Klinisch Moleculair

Gevolgen van PATH project voor NSCLC - Zorg … van PATH project voor NSCLC Hoe tillen we Moleculaire Diagnostiek van NSCLC naar hoger plan ? Ed Schuuring KMBP (Klinisch Moleculair

Adaptive Treatment Strategies Module 1—Day 1 Getting SMART About Developing Individualized Adaptive Health Interventions Methods Work, Chicago, Illinois,

Adaptive Treatment Strategies Module 1—Day 1 Getting SMART About Developing Individualized Adaptive Health Interventions Methods Work, Chicago, Illinois,

NSCLC - Stage IV STAGE IVNSCLC. NSCLC - Stage IV NSCLC Main Drugs Stage IV NAVELBINE:The pivotal drug GEMZAR:Main competitor TAXOL:Still often prescribed.

NSCLC - Stage IV STAGE IVNSCLC. NSCLC - Stage IV NSCLC Main Drugs Stage IV NAVELBINE:The pivotal drug GEMZAR:Main competitor TAXOL:Still often prescribed.